Biblio

Author Title [ Type

] Year

Filters: Author is Lübbert, Michael [Clear All Filters]

Journal Article

Lübbert M, Wijermans PW, Kicinski M, Chantepie S, van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2023;10(11):e879-e889.

Baumann J, Spindler M, Throm Y, Lübbert M, Bender M. Absence of early platelet increment in healthy mice during decitabine treatment. Sci Rep. 2022;12(1):22266.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, et al. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leuk Res. 2018;72:20-26.

Itzykson R, Santini V, Thépot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022:JCO2200437.

May AM, Stomper J, Joeckel TE, Bronsert P, Wijermans PW, Werner M, Lübbert M. Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine. Br J Haematol. 2020.

Goyal A, Bauer J, Hey J, Papageorgiou DN, Stepanova E, Daskalakis M, Scheid J, Dubbelaar M, Klimovich B, Schwarz D, et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun. 2023;14(1):6731.

Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, et al. Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019:JCO1901406.

Schüller H, Klein F, Lübbert M, Prager EPeter. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Ann Hematol. 2020.

Stratmann J, van Kann E, Rummelt C, Koschade S, Röllig C, Lübbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, et al. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leuk Res. 2019;85:106192.

Jung M, Herrlinger E-M, Hau M, Redhaber DMelanie, Greve G, Willmann D, Steimle S, Müller M, Lübbert M, Miething CCornelius, et al. Nitroreductase-mediated release of inhibitors of Lysine-Specific Demethylase 1 (LSD1) from prodrugs in transfected acute myeloid leukaemia cells. Chembiochem. 2020.

Baron F, Efficace F, Cannella L, Stevens-Kroef M, Amadori S, de Witte T, Lübbert M, Venditti A, Suciu S. Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial. Am J Hematol. 2024.